Scarica l'app Stockscreener
1.60
3.90%
0.06
Dopo l'orario di chiusura:
1.62
0.02
+1.25%
Precedente Chiudi:
$1.54
Aprire:
$1.555
Volume 24 ore:
375.47K
Relative Volume:
0.24
Capitalizzazione di mercato:
$85.54M
Reddito:
-
Utile/perdita netta:
$-59.69M
Rapporto P/E:
-1.1511
EPS:
-1.39
Flusso di cassa netto:
$-46.54M
1 W Prestazione:
-4.19%
1M Prestazione:
-9.09%
6M Prestazione:
-21.95%
1 anno Prestazione:
+7.38%
Intervallo 1D:
$1.55
$1.60
Intervallo di 1 settimana:
$1.48
$1.71
Portata 52W:
$0.6254
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Nome
Milestone Pharmaceuticals Inc
Settore
Industria
Telefono
(514) 336-0444
Indirizzo
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Confronta MIST con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.60 | 130.84M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Ripresa | H.C. Wainwright | Buy |
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2023-06-20 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-25 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Iniziato | Oppenheimer | Outperform |
| 2019-06-03 | Iniziato | Cowen | Outperform |
| 2019-06-03 | Iniziato | Jefferies | Buy |
| 2019-06-03 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie
What drives Milestone Pharmaceuticals Inc. stock priceHigh-return market picks - Autocar Professional
Milestone Pharmaceuticals Inc. Stock Analysis and ForecastConsistently exceptional gains - jammulinksnews.com
What analysts say about Milestone Pharmaceuticals Inc. stockConsistently superior profits - Autocar Professional
Is Milestone Pharmaceuticals Inc. a good long term investmentDynamic portfolio growth - Autocar Professional
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution (MIST) - Seeking Alpha
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Cuts Target Price to $4 - 富途牛牛
HC Wainwright Has Positive Estimate for MIST Q3 Earnings - Defense World
Milestone Pharmaceuticals plunges after pricing $52.5M offering - MSN
What makes Milestone Pharmaceuticals Inc. stock price move sharplyTrade Ready Signal - Newser
Why Milestone Pharmaceuticals Inc. stock attracts strong analyst attention10x Potential Stocks - Newser
How Milestone Pharmaceuticals Inc. stock performs during market volatilityPrecision Entry Strategy - Newser
Retail investors who have a significant stake must be disappointed along with institutions after Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) market cap dropped by US$9.0m - simplywall.st
Milestone Pharmaceuticals shares fall 7.37% intraday after FDA acceptance of CARDAMYST Nasal Spray response. - AInvest
Milestone Pharmaceuticals Announces Public Offering for $48.7M - TipRanks
MIST SEC FilingsMilestone Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Milestone Pharmaceuticals Initiates Capital Raise Through Securities Offering - AInvest
CARDAMYST's Regulatory Odyssey Nears Finish Line: Why Milestone Pharmaceuticals is Poised for Liftoff by Q4 2025 - AInvest
Milestone Pharma's $52.5M Warrant Offering: Betting on FDA Approval and PSVT's Untapped Market - AInvest
Milestone Pharmaceuticals' $52.5M Offering: A Risky Gamble or Strategic Lifeline? - AInvest
Milestone Pharmaceuticals (MIST) Announces $52.5M Public Offerin - GuruFocus
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge - Benzinga
Why Is Milestone Pharmaceuticals Stock Plunging On Friday? - Benzinga
Milestone Pharmaceuticals (MIST) Shares Plummet After $52.5 Mill - GuruFocus
Milestone Pharmaceuticals announces pricing of $52.5 million public offering - MarketScreener
Milestone Pharmaceuticals prices $52.5 million public offering - Investing.com India
Milestone Pharmaceuticals prices $52.5 million public offering By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Pub - GuruFocus
Milestone Pharmaceuticals Plummets 39%—What’s Behind the Freefall? - AInvest
Milestone Pharmaceuticals Shares Drop Sharply After Public Offering Announcement - MSN
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants - TradingView
Milestone Pharmaceuticals Secures $52.5M Funding to Advance Breakthrough PSVT Heart Treatment - Stock Titan
Navigating the Dilution Crossroads: Milestone Pharmaceuticals' Financing – Gateway or Value Trap? - AInvest
Milestone Pharmaceuticals Poised to Break Through with CARDAMYST: A Strategic Play Ahead of FDA's December Decision - AInvest
Milestone Pharmaceuticals stock plunges on public offering announcement By Investing.com - Investing.com Nigeria
Milestone Pharmaceuticals Inc Azioni (MIST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):